Skip to main content

Table 5 NIS gene therapy in extrathyroidal neoplasia

From: Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer

Neoplasia

Vector

Combined treatments (*)

Promoter (**)

References

Neuroblastoma

Plasmid-polyplex

 

CMV

[88]

Medulloblastoma

MV

+

 

[89]

Glioma

Ad

 

CMV

[90]

Retrovirus

 

LTR

[91]

Multiple myeloma

MV

+

 

[92]

VSV

+

 

[93]

Melanoma

Ad

 

TR/TERT

[44]

Mesothelioma

MV

+

 

[94]

Colon cancer

Ad

 

CMV

[95]

Ad

 

CMV/CEA

[96]

Lentivirus

 

UbC

[97]

Lentivirus

+

UbC

[98]

Ad

+

CMV

[99]

Ad

 

TERT, TR

[44]

MV

+

 

[100]

Colorectal cancer

Ad

+

Wnt-responsiveTCF4

[101]

Ad

+

TR

[102]

Hepatoma

Ad

 

HIP

[103]

Plasmid

 

AFP

[104]

Retrovirus

+

CMV

[105]

Retrovirus

+

TERT

[106]

 

Plasmid-polyplex

 

CMV

[107]

NIS-MSC

 

CMV in MSC

[108]

PAMAM-Ad

 

CMV

[109]

Pancreatic cancer

Ad

 

MUC1

[110]

MV

+

 

[111]

Ad

+

E3

[82]

 

Ad

 

Survivin

[112]

Cervical cancer

Retrovirus

+

CMV

[105]

  1. (*): to enhance the tumor growth inhibition; (**): tumor cells-specific promoter.
  2. Abbreviations: polyplex synthetic polymeric vector, CMV cytomegalovirus, MV measles virus, Ad adenovirus, LTR long terminal repeat, VSV vesicular stomatitis virus, TR telomerase RNA, TERT telomerase reverse transcriptase, CEA carcinoembryonic antigen, UbC ubiquitin C, Wnt Wingless-related integration site, TCF4 transcription factor 4, PAMAM-Ad adenoviral vectors after coating with synthetic poly(amidoamine) dendrimers, HIP hepatocarcinoma-intestine-pancreas gene, AFP alpha-fetoprotein, MSC mesenchymal stem cells, MUC1 mucin1 gene, E3 E3 antigen.